Heart Failure

Heart Failure Pharmacology: The Clinical Logic
Connect heart failure phenotypes and hemodynamics with disease-modifying therapies, decongestion, acute stabilization, and safe prescribing and monitoring.

Course Content

01. Heart Failure Pharmacology: The Clinical Logic
02. Hemodynamics: Where Heart Failure Drugs Act
03. The Pathophysiologic Loop of HFrEF
04. Neurohormonal Targets in Heart Failure
05. HFrEF: The Four Mortality-Modifying Pillars
06. Pillar 1: ACE Inhibitors, ARBs, and ARNIs
07. ARNI Mechanism and the 36-Hour Rule
08. Pillar 2: Evidence-Based Beta Blockers
09. Pillar 3: Mineralocorticoid Receptor Antagonists
10. Pillar 4: SGLT2 Inhibitors
11. HFmrEF and HFpEF Pharmacology
12. Diuretics: Decongestion, Not Disease Modification
13. Diuretic Resistance and Sequential Nephron Blockade
14. Digoxin: Inotropy With a Narrow Therapeutic Window
15. Add-On HFrEF Therapies
16. Acute Decompensated Heart Failure: First Classification
17. Acute Decompensated HF: Treatment by Hemodynamic Profile
18. Inotropes, Vasodilators, and Vasopressors in Acute HF
19. Monitoring and Prescribing Safety
20. Drugs That Worsen Heart Failure
21. Integrated Board-Style Clinical Reasoning
Scroll to Top